Compare ADMA Biologics Inc (ADMA) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Yum! Brands, Inc. — how do they compare? ADMA Biologics Inc trades at $9.92 (market cap $2.22B), while Yum! Brands, Inc. trades at $149.05 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 17.8× ADMA Biologics Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | YUM | |
|---|---|---|
Market Cap | $2.22B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $168.16 |
52-Week Low | $7.60 | $138.21 |
Enterprise Value | $2.29B | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
YUM trades at $145.33, down 3.6% amid bearish technical signals and recent parasite outbreak concerns affecting Taco Bell sales. The company reported strong Q2 2026 earnings of $1.62 per share, beating estimates, with revenue growth continuing from $8.21B in 2025 to projected $8.7B in 2026. Valuation metrics show a P/E of 18.23 and P/S of 4.63, while debt reduction improved with debt-to-asset ratio declining to 143.49 in 2025.
The outlook remains mixed with analyst consensus price target of $174.60 suggesting 20% upside, but legal investigations and food safety issues pose near-term risks. Long-term growth drivers include digital expansion and portfolio optimization following Pizza Hut China sale, though execution on Taco Bell recovery is critical for sentiment improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
